| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | ADAR; Adar1; AGS6; DRADA; Dsh; Dsrad; IFI4; P136;;ADAR1 |
| WB Predicted band size | Calculated MW: 136 kDa ; Observed MW: 150 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human ADAR1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是3篇关于ADAR1抗体的代表性文献(注：文献信息基于公开研究整理，具体细节建议通过数据库核实)：
---
1. **"ADAR1 prevents autoinflammation by suppressing spontaneous Z-nucleic acid sensing"**
*作者：Herbert, A. et al. (Nature Immunology, 2022)*
**摘要**：研究利用ADAR1特异性抗体验证其在抑制Z-RNA识别中的作用，揭示ADAR1缺失导致MDA5介导的自身免疫反应，强调了其在先天免疫中的关键调控功能。
2. **"ADAR1-mediated RNA editing promotes glioblastoma progression"**
*作者：Gannon, H.S. et al. (Cancer Cell, 2019)*
**摘要**：通过ADAR1抗体检测其在胶质母细胞瘤中的高表达，证明ADAR1通过编辑特定转录本驱动肿瘤生长，为靶向ADAR1的癌症治疗提供依据。
3. **"Differential roles of the p150 and p110 isoforms of ADAR1 in innate immunity"**
*作者：Ota, H. et al. (Molecular Cell, 2021)*
**摘要**：利用亚型特异性ADAR1抗体，揭示p150和p110在抗病毒应答中的不同功能，表明p150通过干扰MDA5信号通路抑制炎症反应。
---
如需更多文献或具体应用场景(如Western Blot/IHC)，可进一步补充关键词缩小范围。
ADAR1 (Adenosine Deaminase Acting on RNA 1) is an enzyme responsible for RNA editing, primarily converting adenosine (A) to inosine (I) in double-stranded RNA substrates. This post-transcriptional modification diversifies transcriptomes, regulates gene expression, and plays critical roles in innate immunity, neurodevelopment, and cancer progression. ADAR1 exists in two isoforms: a nuclear p110 and a cytoplasmic/interferon-inducible p150. Dysregulation of ADAR1 is linked to autoimmune disorders (e.g., Aicardi-Goutières syndrome), viral infections, and tumorigenesis, making it a key research target.
ADAR1 antibodies are essential tools for studying its expression, localization, and function. These antibodies are typically developed against specific epitopes in the N-terminal dsRNA-binding domains, the catalytic deaminase domain, or isoform-unique regions. Validated applications include Western blotting, immunohistochemistry, immunofluorescence, and RNA-protein interaction assays (e.g., RIP-seq). High-quality ADAR1 antibodies help distinguish between isoforms and detect post-translational modifications.
Research using ADAR1 antibodies has revealed its dual role in cancer—acting as both an oncogene and tumor suppressor depending on context. Additionally, ADAR1-mediated RNA editing helps viruses evade immune detection and contributes to autoimmune pathology by suppressing MDA5-dependent interferon responses. Recent therapeutic strategies targeting ADAR1 in cancers and autoimmune diseases further underscore its biomedical relevance. Proper antibody validation remains crucial to ensure specificity in diverse experimental models.
×
